现代中西医结合杂志
現代中西醫結閤雜誌
현대중서의결합잡지
MODERN JOURNAL OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE
2015年
3期
229-231,234
,共4页
老年人%Ⅲb~Ⅳ期非小细胞肺癌%肺癌Ⅰ号方%化疗
老年人%Ⅲb~Ⅳ期非小細胞肺癌%肺癌Ⅰ號方%化療
노년인%Ⅲb~Ⅳ기비소세포폐암%폐암Ⅰ호방%화료
elderly patients%intermediate and advanced no-small cell lung cancer%Lung canderⅠprescription%chem-otherapy
目的：观察肺癌I号方联合化疗治疗老年期非小细胞肺癌的临床疗效。方法将90例患者按完全随机原则分为3组，Ⅰ组30例给予紫杉醇、卡铂化疗，Ⅱ组30例给肺癌1号方治疗，Ⅲ组30例给予肺癌Ⅰ号方联合化疗，3周为1个周期，治疗2个周期后比较3组近期疗效及KPS评分、体质量等指标的改善情况及不良反应发生情况。结果Ⅰ组、Ⅲ组有效率显著高于Ⅱ组（P均＜0．05），Ⅲ组与Ⅰ组比较差异无统计学意义（P＞0．05）；治疗后Ⅱ组、Ⅲ组生活质量均较治疗前显著改善（ P均＜0．05），组间比较差异无统计学意义（ P＞0．．05），Ⅰ组改善不明显；治疗后Ⅱ组、Ⅲ组体质量增加，与I组比较差异有统计学意义（P均＜0．05）；Ⅲ组不良反应较Ⅰ组显著减轻（P＜0．05），Ⅱ组无明显不良反应。结论肺癌Ⅰ号方能够提高老年Ⅲ～Ⅳ期非小细胞肺癌患者的生活质量，联合化疗时可减轻化疗不良反应，提高疗效。
目的：觀察肺癌I號方聯閤化療治療老年期非小細胞肺癌的臨床療效。方法將90例患者按完全隨機原則分為3組，Ⅰ組30例給予紫杉醇、卡鉑化療，Ⅱ組30例給肺癌1號方治療，Ⅲ組30例給予肺癌Ⅰ號方聯閤化療，3週為1箇週期，治療2箇週期後比較3組近期療效及KPS評分、體質量等指標的改善情況及不良反應髮生情況。結果Ⅰ組、Ⅲ組有效率顯著高于Ⅱ組（P均＜0．05），Ⅲ組與Ⅰ組比較差異無統計學意義（P＞0．05）；治療後Ⅱ組、Ⅲ組生活質量均較治療前顯著改善（ P均＜0．05），組間比較差異無統計學意義（ P＞0．．05），Ⅰ組改善不明顯；治療後Ⅱ組、Ⅲ組體質量增加，與I組比較差異有統計學意義（P均＜0．05）；Ⅲ組不良反應較Ⅰ組顯著減輕（P＜0．05），Ⅱ組無明顯不良反應。結論肺癌Ⅰ號方能夠提高老年Ⅲ～Ⅳ期非小細胞肺癌患者的生活質量，聯閤化療時可減輕化療不良反應，提高療效。
목적：관찰폐암I호방연합화료치료노년기비소세포폐암적림상료효。방법장90례환자안완전수궤원칙분위3조，Ⅰ조30례급여자삼순、잡박화료，Ⅱ조30례급폐암1호방치료，Ⅲ조30례급여폐암Ⅰ호방연합화료，3주위1개주기，치료2개주기후비교3조근기료효급KPS평분、체질량등지표적개선정황급불량반응발생정황。결과Ⅰ조、Ⅲ조유효솔현저고우Ⅱ조（P균＜0．05），Ⅲ조여Ⅰ조비교차이무통계학의의（P＞0．05）；치료후Ⅱ조、Ⅲ조생활질량균교치료전현저개선（ P균＜0．05），조간비교차이무통계학의의（ P＞0．．05），Ⅰ조개선불명현；치료후Ⅱ조、Ⅲ조체질량증가，여I조비교차이유통계학의의（P균＜0．05）；Ⅲ조불량반응교Ⅰ조현저감경（P＜0．05），Ⅱ조무명현불량반응。결론폐암Ⅰ호방능구제고노년Ⅲ～Ⅳ기비소세포폐암환자적생활질량，연합화료시가감경화료불량반응，제고료효。
Objective It is to observe the therapeutic effect of Lung cancerⅠprescription combined with chemotherapy in elderly patients with non -small cell long -cancer ( NSCLC ) .Methods Ninety patients with intermediate and advanced NSCLC were equally randomized into 3 groups.The patients were treated with routine chemical therapy ( TP) in GroupⅠand with Lung cancer Ⅰ prescription in Group Ⅱand with TP combined with Lung cancer Ⅰ prescription in Group Ⅲ.Three weeks constituted one phase, two phases constituted one treatment courses, and the treatment lasted 2 courses.The changes of tumor mass, quality of life, body weight as well as toxic and side reactions were observed in the three groups.Results The ef-fective rate on reducing tumor mass was 40%in groupⅠand 46.67%in groupⅢ , they were higher than 16.67%in groupⅡ(all P<0.05).The quality of life were improved obviously in groupsⅡandⅢcompared with before treatment (all P<0.05), but there was no significant difference between them (P>0.05), and the changes was little in groupⅠ.The effec-tive rate on body weight was 87%in groupⅡand 80%in groupⅢ, they were markedly higher than 43%in groupⅠ( P<0.05) .No obvious toxic and side reactions was found in groupⅡ, and the relief of toxic and reactions in groupⅢwere light-ened obviously compared with groupⅠ(P<0.05).Conclusion Lung cancerⅠprescription can increase quality of life, re-duce the toxic and side reactions induced by chemical therapy in the elderly patients with NSCLC.
